# OlympiAD (NCT02000622)

> Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02000622
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: AstraZeneca
- Conditions: Breast Cancer Metastatic; BRCA 1 Gene Mutation; BRCA 2 Gene Mutation
- Interventions: Olaparib; Physician's choice chemotherapy
- Enrollment: 302
- Primary outcome: Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1)

## Commentary we found

- YouTube: 35
- Podcasts: 24
- X threads: 6

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=olympiad-nct02000622

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02000622", "email": "<work email>"}; the inbox owner confirms by the emailed link.